Compare ARCO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | IOVA |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2011 | 2008 |
| Metric | ARCO | IOVA |
|---|---|---|
| Price | $8.03 | $3.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.60 | ★ $9.11 |
| AVG Volume (30 Days) | 1.1M | ★ 18.8M |
| Earning Date | 03-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.64 | $51.55 |
| Revenue Next Year | $6.59 | $37.55 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $1.64 |
| 52 Week High | $8.98 | $5.63 |
| Indicator | ARCO | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 47.90 |
| Support Level | $7.99 | $2.02 |
| Resistance Level | $8.06 | $4.34 |
| Average True Range (ATR) | 0.26 | 0.44 |
| MACD | -0.04 | -0.15 |
| Stochastic Oscillator | 49.11 | 3.22 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.